


RealRate

## PHARMACEUTICAL 2021



## Keros Therapeutics Inc. Rank 16 of 402





## PHARMACEUTICAL 2021



## Keros Therapeutics Inc. Rank 16 of 402



The relative strengths and weaknesses of Keros Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Keros Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Keros Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 292%, being 245% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	267,726
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	7,184
Liabilities, Non-Current	538
Other Assets	993
Other Compr. Net Income	0
Other Expenses	-172
Other Liabilities	0
Other Net Income	1,124
Other Revenues	0
Property and Equipment	724
Research and Development	33,860
Selling, General and Administrative Expense	12,797

Output Variable	Value in 1000 USD
Assets	269,443
Liabilities	7,722
Expenses	46,485
Revenues	0
Stockholders Equity	261,721
Net Income	-45,361
Comprehensive Net Income	-45,361
Economic Capital Ratio	292%

